NCT02070458View on ClinicalTrials.gov

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 8, 2014

Primary Completion Date

March 17, 2017

Study Completion Date

August 15, 2017

Conditions
Recurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

ixazomib

Given PO

DRUG

mitoxantrone hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

cytarabine

Given IV

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44106-5065

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT02070458 - Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter